3-Amino-1-Adamantanol CAS 702-82-9 Purity >99.0% (HPLC) Factory

Short Description:

Chemical Name: 3-Amino-1-Adamantanol

CAS: 702-82-9

Appearance: White Crystalline Powder

Purity: >99.0% (HPLC) (dry basis)

Intermediate of API (CAS 274901-16-5) in the treatment of Type 2 Diabetes Mellitus (T2DM)

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply Related Intermediates:
CAS: 274901-16-5
3-Amino-1-Adamantanol CAS: 702-82-9
L-Prolinamide CAS: 7531-52-4
Boc-L-Proline CAS: 15761-39-4
(2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile CAS: 207557-35-5

Chemical Properties:

Chemical Name	3-Amino-1-Adamantanol
Synonyms	1-Amino-3-Hydroxyadamantane; 3-Amino-1-Hydroxyadamantane
CAS Number	702-82-9
CAT Number	RF-PI102
Stock Status	In Stock, Production Capacity 800MT/Year
Molecular Formula	C₁₀H₁₇NO
Molecular Weight	167.25
Solubility	Soluble in Organic Solvents and Insoluble in Water
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White Crystalline Powder
Purity / Analysis Method	>99.0% (HPLC) (dry basis)
Water (by Karl Fischer)	<0.50%
Residue on Ignition	<0.50%
Melting Point	266.5℃~272.5℃
Single Impurity	<0.50%
Total Impurities	<1.00%
Infrared Spectrum	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Intermediate of API (CAS: 274901-16-5)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light & moisture

Advantages:

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 3-Amino-1-Adamantanol (CAS: 702-82-9) with high quality. API (CAS: 274901-16-5) is synthesised from 3-Amino-1-Adamantanol. API (CAS: 274901-16-5) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. API (CAS: 274901-16-5) inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. It has been shown to reduce hyperglycemia in type 2 diabetes mellitus. It was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.